Mylan Company Profile (NASDAQ:MYL)

About Mylan

Mylan logoMylan N.V., formerly Mylan Inc., is a global pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. Mylan operates in two segments: Generics and Specialty. The Company's generic pharmaceutical business is conducted primarily in the United States and Canada (collectively, North America); Europe, the Middle East, and Africa (collectively, EMEA); and India, Australia, Japan and New Zealand (collectively, Asia Pacific). Its specialty pharmaceutical business is conducted by Mylan Specialty L.P. (Mylan Specialty). The Company's API business is conducted through Mylan Laboratories Limited (Mylan India), which is included within the Asia Pacific region in its Generics Segment. Mylan provides products to customers in approximately 140 countries and territories.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: MYL
  • CUSIP: 62853010
Key Metrics:
  • Previous Close: $43.15
  • 50 Day Moving Average: $46.84
  • 200 Day Moving Average: $45.43
  • Trailing P/E Ratio: 27.31
  • Foreward P/E Ratio: 7.43
  • P/E Growth: 0.64
  • Market Cap: $23.08B
  • Outstanding Shares: 534,911,000
  • Beta: 1.25
Additional Links:
Companies Related to Mylan:

Analyst Ratings

Consensus Ratings for Mylan (NASDAQ:MYL) (?)
Ratings Breakdown: 7 Hold Ratings, 8 Buy Ratings
Consensus Rating:Buy (Score: 2.53)
Consensus Price Target: $58.67 (35.96% upside)

Analysts' Ratings History for Mylan (NASDAQ:MYL)
DateFirmActionRatingPrice TargetDetails
8/24/2016Bank of America Corp.Reiterated RatingBuy$70.00View Rating Details
8/15/2016Leerink SwannBoost Price TargetOutperform$51.00 -> $55.00View Rating Details
7/12/2016Morgan StanleyReiterated RatingHoldView Rating Details
6/25/2016JPMorgan Chase & Co.Reiterated RatingOverweightView Rating Details
5/13/2016Goldman Sachs Group Inc.DowngradeConviction-Buy -> Buy$60.00View Rating Details
3/21/2016Wells Fargo & Co.Reiterated RatingMarket PerformView Rating Details
3/8/2016BTIG ResearchReiterated RatingBuy$60.00View Rating Details
2/19/2016ArgusLower Price TargetBuy$65.00 -> $55.00View Rating Details
2/11/2016Citigroup Inc.Reiterated RatingBuyView Rating Details
2/11/2016GuggenheimReiterated RatingNeutralView Rating Details
2/11/2016Royal Bank Of CanadaReiterated RatingHold$60.00 -> $58.00View Rating Details
2/11/2016Cowen and CompanyLower Price TargetMarket Perform$65.00 -> $55.00View Rating Details
11/16/2015BMO Capital MarketsLower Price TargetMarket Perform$46.00View Rating Details
9/21/2015Barclays PLCInitiated CoverageEqual Weight$57.00View Rating Details
8/26/2015Standpoint ResearchInitiated CoverageBuy$70.00View Rating Details
8/12/2015SusquehannaLower Price TargetPositive$85.00 -> $68.00View Rating Details
8/7/2015Deutsche Bank AGReiterated RatingBuy$65.00 -> $66.00View Rating Details
8/7/2015Sanford C. BernsteinLower Price Target$83.00 -> $60.00View Rating Details
6/18/2015B. RileyInitiated CoverageBuy$85.00 -> $71.23View Rating Details
6/3/2015Raymond James Financial Inc.Initiated CoverageMarket PerformView Rating Details
4/22/2015CRT CapitalBoost Price TargetBuy$68.00 -> $87.00View Rating Details
10/6/2014S&P Equity ResearchReiterated RatingBuyView Rating Details
10/6/2014ING GroupReiterated RatingBuy$68.00View Rating Details
9/4/2014Evercore ISIInitiated CoverageHoldView Rating Details
(Data available from 8/25/2014 forward)


Earnings History for Mylan (NASDAQ:MYL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2016Q216$1.13$1.16$2.58 billion$2.56 billionViewN/AView Earnings Details
5/3/2016Q116$0.74$0.76$2.23 billion$2.19 billionViewN/AView Earnings Details
2/10/2016Q415$1.27$1.22$2.71 billion$2.49 billionViewListenView Earnings Details
10/30/2015Q315$1.38$1.43$2.79 billion$2.71 billionViewListenView Earnings Details
8/6/2015Q215$0.89$0.91$2.39 billion$2.37 millionViewN/AView Earnings Details
5/5/2015Q115$0.69$0.70$1.87 billionViewListenView Earnings Details
3/2/2015Q414$1.05$1.05$2.07 billion$2.08 billionViewListenView Earnings Details
10/30/2014Q314$1.14$1.16$2.06 billion$2.08 billionViewN/AView Earnings Details
8/7/2014Q214$0.73$0.69$1.88 billion$1.84 billionViewN/AView Earnings Details
5/1/2014Q114$0.68$0.66$1.80 billion$1.72 billionViewN/AView Earnings Details
2/27/2014Q413$0.75$0.78$1.81 billion$1.81 billionViewN/AView Earnings Details
10/31/2013Q313$0.79$0.82$1.84 billion$1.77 billionViewN/AView Earnings Details
8/1/2013Q2 2013$0.67$0.68$1.73 billion$1.70 billionViewN/AView Earnings Details
5/2/2013Q1 2013$0.62$0.62$1.69 billion$1.63 billionViewN/AView Earnings Details
2/27/2013Q4 2012$0.64$0.65$1.73 billion$1.72 billionViewN/AView Earnings Details
10/25/2012$0.77$0.83ViewN/AView Earnings Details
7/26/2012$0.55$0.60ViewN/AView Earnings Details
4/26/2012$0.51$0.52ViewN/AView Earnings Details
2/21/2012$0.50$0.53ViewN/AView Earnings Details
10/26/2011$0.51$0.55ViewN/AView Earnings Details
7/27/2011$0.45$0.52ViewN/AView Earnings Details
5/3/2011$0.44$0.44ViewN/AView Earnings Details
2/24/2011$0.45$0.45ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Mylan (NASDAQ:MYL)
Current Year EPS Consensus Estimate: $4.97 EPS
Next Year EPS Consensus Estimate: $5.81 EPS


Dividend History for Mylan (NASDAQ:MYL)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Mylan (NASDAQ:MYL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/9/2016Heather M BreschCEOSell100,200$50.00$5,010,000.00View SEC Filing  
6/3/2016Joseph C Md MaroonDirectorBuy1,670$44.95$75,066.50View SEC Filing  
5/25/2016Robert J CindrichDirectorBuy1,190$42.47$50,539.30View SEC Filing  
5/12/2016Melina E HigginsDirectorBuy19,900$38.68$769,732.00View SEC Filing  
5/6/2016Melina E HigginsDirectorBuy100$38.69$3,869.00View SEC Filing  
4/28/2016Melina E HigginsDirectorBuy35,000$42.92$1,502,200.00View SEC Filing  
4/5/2016Robert J CouryChairmanSell217,755$45.96$10,008,019.80View SEC Filing  
3/31/2016Joseph C Md MaroonDirectorBuy4,337$46.36$201,063.32View SEC Filing  
3/17/2016Mark W ParrishDirectorBuy1,705$44.00$75,020.00View SEC Filing  
3/8/2016Wendy CameronDirectorBuy2,190$45.69$100,061.10View SEC Filing  
3/3/2016Robert J CindrichDirectorBuy2,187$45.83$100,230.21View SEC Filing  
12/17/2015John D. SheehanCFOSell34,579$55.03$1,902,882.37View SEC Filing  
6/15/2015Melina E HigginsDirectorSell8,351$73.08$610,291.08View SEC Filing  
2/3/2015Anthony MauroInsiderSell13,255$53.15$704,503.25View SEC Filing  
2/3/2015Heather M BreschCEOSell411,996$53.15$21,897,587.40View SEC Filing  
2/3/2015Rajiv MalikPresidentSell285,394$53.15$15,168,691.10View SEC Filing  
2/3/2015Robert J CouryChairmanSell947,119$52.55$49,771,103.45View SEC Filing  
2/3/2015Rodney L PiattDirectorSell46,000$53.15$2,444,900.00View SEC Filing  
11/26/2014John D SheehanCFOSell19,475$57.50$1,119,812.50View SEC Filing  
11/25/2014Heather M BreschCEOSell100,000$55.80$5,580,000.00View SEC Filing  
11/25/2014Rajiv MalikPresidentSell120,000$55.78$6,693,600.00View SEC Filing  
11/25/2014Robert J CouryChairmanSell165,700$55.78$9,242,746.00View SEC Filing  
11/24/2014Heather M BreschCEOSell80,222$55.86$4,481,200.92View SEC Filing  
11/24/2014Rajiv MalikPresidentSell84,300$55.86$4,708,998.00View SEC Filing  
11/24/2014Robert J CouryChairmanSell105,800$55.88$5,912,104.00View SEC Filing  
11/7/2014Melina E HigginsDirectorBuy14,000$52.45$734,300.00View SEC Filing  
9/18/2014Neil F DimickDirectorSell5,432$48.26$262,148.32View SEC Filing  
6/19/2014Neil F DimickDirectorSell5,432$50.81$275,999.92View SEC Filing  
4/22/2014Rajiv MalikPresidentSell80,000$50.00$4,000,000.00View SEC Filing  
4/14/2014Heather BreschCEOSell75,000$46.07$3,455,250.00View SEC Filing  
3/20/2014Neil DimickDirectorSell5,813$53.08$308,554.04View SEC Filing  
3/14/2014C ToddDirectorSell10,000$53.00$530,000.00View SEC Filing  
3/6/2014Harry KormanCOOSell31,970$54.54$1,743,643.80View SEC Filing  
3/3/2014Anthony MauroInsiderSell20,000$54.81$1,096,200.00View SEC Filing  
3/3/2014Daniel Rizzo, Jr.CAOSell8,003$55.50$444,166.50View SEC Filing  
3/3/2014Douglas LeechDirectorSell10,000$55.40$554,000.00View SEC Filing  
1/2/2014Neil DimickDirectorSell5,813$43.15$250,830.95View SEC Filing  
12/19/2013Rodney PiattDirectorSell10,000$41.84$418,400.00View SEC Filing  
12/12/2013Daniel Rizzo, Jr.CAOSell70,683$42.04$2,971,513.32View SEC Filing  
12/12/2013Melina HigginsDirectorBuy5,000$42.03$210,150.00View SEC Filing  
9/6/2013Heather M BreschCEOSell160,000$35.35$5,656,000.00View SEC Filing  
6/3/2013Neil F DimickDirectorSell19,994$30.51$610,016.94View SEC Filing  
11/27/2012Daniel C Rizzo JrCAOSell161,124$27.28$4,395,462.72View SEC Filing  
11/2/2012Douglas J LeechDirectorSell44,280$25.94$1,148,623.20View SEC Filing  
11/1/2012Anthony MauroInsiderSell12,301$25.79$317,242.79View SEC Filing  
10/5/2012Anthony MauroInsiderSell12,296$24.84$305,432.64View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Mylan (NASDAQ:MYL)
DateHeadline logoA Cheaper Option To The EpiPen (NASDAQ:MYL) - August 24 at 6:54 PM logoSocial Sentiment On Mylan Is Nearly Unanimously Negative, And Could Benefit A Competitor (NASDAQ:MYL) - August 24 at 6:54 PM logoThe Wall Street Journal: Backlash grows against Mylan’s EpiPen price hikes (NASDAQ:MYL) - August 24 at 6:37 PM logoUPDATE 1-Mylan wins round in fight with Teva over multiple sclerosis drug (NASDAQ:MYL) - August 24 at 6:07 PM logoStock losses firm as slide in Mylan shares punish health-care sector (NASDAQ:MYL) - August 24 at 6:07 PM
News IconMylan Pharmaceuticals urged to rein in exorbitant EpiPen costs (NASDAQ:MYL) - August 24 at 6:07 PM
News IconAnother black eye for Pharma (NASDAQ:MYL) - August 24 at 6:07 PM
News IconEpiPen Maker Mylan Also Hiked Prices on other Medications (NASDAQ:MYL) - August 24 at 6:07 PM logoClinton calls Mylan EpiPen pricing 'outrageous' (NASDAQ:MYL) - August 24 at 6:07 PM logoSen. Manchin mum on EpiPen hikes by daughter's drug company (NASDAQ:MYL) - August 24 at 6:07 PM logoShares of Teva Pharmaceuticals fall after US Patent Office invalidates two patents (NASDAQ:MYL) - August 24 at 6:07 PM logo​Seattle biotech stocks reeling after Hillary Clinton criticizes drug prices (NASDAQ:MYL) - August 24 at 6:07 PM logo[$$] Mylan Faces Scrutiny Over EpiPen Price Increases (NASDAQ:MYL) - August 24 at 6:07 PM logoBacklash grows against Mylan’s EpiPen price hikes (NASDAQ:MYL) - August 24 at 6:07 PM logoClinton calls for reduction in cost of allergy drug EpiPen (NASDAQ:MYL) - August 24 at 1:36 PM logoHave You Heard About This Generic EpiPen Maker? (NASDAQ:MYL) - August 24 at 9:43 AM logoSJM, MYL and ZOES stock used more than their fair share of red ink on Tuesday (NASDAQ:MYL) - August 24 at 9:27 AM logoTwo Senators Investigate Pricing of Mylan's EpiPen (MYL) (NASDAQ:MYL) - August 24 at 9:27 AM logoThe Senator’s Daughter Who Raised Prices on Anti-Allergy EpiPen (NASDAQ:MYL) - August 24 at 9:27 AM logoExecutive Edge: EpiPen price controversy (NASDAQ:MYL) - August 24 at 9:27 AM logoMylan (MYL) Draws Flak for Over Pricing EpiPen, Stock Down (NASDAQ:MYL) - August 24 at 9:27 AM logoMylan NV breached its 50 day moving average in a Bearish Manner : MYL-US : August 24, 2016 (NASDAQ:MYL) - August 24 at 9:27 AM logoMylan Inc. (NASDAQ:MYL) Reports Accounts Payable Of $1017.6 - (NASDAQ:MYL) - August 23 at 6:31 PM logoMylan Inc. (NASDAQ:MYL) Stock Price Likely To Reach $59.166: Wall Street - (NASDAQ:MYL) - August 23 at 6:31 PM logoMylan slumps on senator's inquiry into EpiPen price hikes - Seeking Alpha (NASDAQ:MYL) - August 23 at 6:31 PM logoHow EpiPen's maker raised prices, and hackles, so much (NASDAQ:MYL) - August 23 at 6:31 PM logoWhy J M Smucker Co (SJM), Mylan NV (MYL) and Zoe’s Kitchen Inc (ZOES) Are 3 of Today’s Worst Stocks (NASDAQ:MYL) - August 23 at 5:24 PM logoWhy J M Smucker Co (SJM), Mylan NV (MYL) and Zoe’s Kitchen Inc (ZOES) Are 3 of Today’s Worst Stocks (NASDAQ:MYL) - August 23 at 5:16 PM logoEpiPen Outrage: Mylan NV (MYL) Hasn’t Learned Squat (NASDAQ:MYL) - August 23 at 12:29 PM logoMylan: In EpiPen Controversy, Shades of Valeant (NASDAQ:MYL) - August 23 at 10:46 AM
News IconGrassley Concerned About Rising Cost Of EpiPens (NASDAQ:MYL) - August 22 at 6:20 PM
News IconValeant, attempting to normalize operations, names new CFO (NASDAQ:MYL) - August 22 at 10:58 AM
News IconMen behind the silver moment (NASDAQ:MYL) - August 21 at 5:42 PM logoSheppard Mullin Adds Crowell & Moring Gov't Contracts Pro (NASDAQ:MYL) - August 20 at 6:04 PM
News IconMartin Shkreli Weighs in on EpiPen Scandal, Calls Drug Makers 'Vultures' (NASDAQ:MYL) - August 20 at 10:25 AM logoSheppard Mullin Adds Crowell & Moring Govt. Contracts Pro (NASDAQ:MYL) - August 20 at 10:25 AM logoMylan shares down on 500% price hike (NASDAQ:MYL) - August 19 at 6:16 PM logoMylan (MYL) Stock Slides on EpiPen Price Criticism (NASDAQ:MYL) - August 19 at 6:16 PM logoMylan Is Expected to Witness Robust Revenue Growth in 2016 (NASDAQ:MYL) - August 18 at 9:28 AM
News IconAnalyst Rating Update on Mylan Inc. (NASDAQ:MYL) | Kentucky News - Post News (NASDAQ:MYL) - August 17 at 6:36 PM logo[$$] Four Picks for a Specialty Pharma Comeback (NASDAQ:MYL) - August 17 at 6:36 PM logoUCB's Anti-Convulsant Patent Is Valid, Delaware Judge Rules (NASDAQ:MYL) - August 16 at 6:31 PM
News IconPulmatrix Scientist Describes Advances in Inhaled Drug Delivery (NASDAQ:MYL) - August 15 at 6:33 PM logoPulmatrix Inc : Pulmatrix Scientist Describes Advances in Inhaled Drug Delivery (NASDAQ:MYL) - August 15 at 6:33 PM
News IconUS price of EpiPen for allergic reactions skyrockets (NASDAQ:MYL) - August 12 at 6:25 PM logoMylan NV :MYL-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 (NASDAQ:MYL) - August 12 at 6:25 PM logoMYLAN N.V. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obl (NASDAQ:MYL) - August 11 at 6:45 PM logoBreathing Easier: Pharma Successfully Leveraging Smoother EU Regulatory Specs (NASDAQ:MYL) - August 11 at 9:31 AM
News IconAllyson Huhn (NASDAQ:MYL) - August 10 at 6:46 PM logoMomenta Pharmaceuticals, Inc.: Good News from Courts and the FDA Ahead? (NASDAQ:MYL) - August 10 at 6:46 PM


Mylan (NASDAQ:MYL) Chart for Thursday, August, 25, 2016

Last Updated on 8/25/2016 by Staff